Please assess the completion status of the following clinical trial:

Trial Title: Rasburicase (Fasturtec) Registration Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At high risk of malignancy and/or chemotherapy-induced hyperuricemia~* Performance status less than 3 on ECOG scale or more than 30% KPS scale~* Uric acid concentrations ≥ 8.0mg/dL~* Suffering from non-Hodgkin's lymphoma Stage more than III, or acute lymphoblastic leukemia with peripheral with blood cell count more than 25,000/mm3, or any lymphoma or leukemia~Exclusion Criteria:~* Treatment with an investigational drug at any time during the 14-day study period (except for agents that are permitted by the Sponsor)~* Pregnancy or lactation~* Prior treatment with Uricozyme or Rasburicase~* Scheduled to receive asparaginase either 24 hours after the first dose of rasburicase~* Treatment with Allopurinol within the seven days preceding study Day 1~* History of significant atopic allergy problems or documented history of asthma~* History of severe reaction to allopurinol~* Known history of glucose-6-phosphate dehydrogenase deficiency.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): IV infusion at a dose level of 0.20mg/kg per day
- 2 (Type: ACTIVE_COMPARATOR): 100mg tablets, administered orally, according to standard medical practice

Based on this trial design, predict the completion outcome and termination type (if applicable).